Sign in
Enrolling by invitationNo phase

Liver health in transgender people taking gender-affirming hormone therapy

Looks at liver health in transgender adults who take hormone therapy.

Key facts

Who runs it
Corey DeStefano
Where
Newark, United StatesSee the site
Trial code
Registry title
North Jersey Community Research Initiative (NJCRI) Study on Transgender Liver Health
Status
Enrolling by invitation
People taking part
60 people, planned
Started
15 Mar 2025
Expected to end
15 Mar 2027
Type of study
Observational
Record updated
5 August 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for transgender adults on gender-affirming hormone therapy (GAHT) to study their liver health. Half have been on GAHT more than 6 months, half less than 6 months.

Age
18 years or older
Sex
All sexes. Participants must be transgender.
Earlier treatment
People must be on GAHT. Half the group has been on it more than 6 months (182 days or more), half less than 6 months (less than 181 days).

Main reasons for not taking part

  • Not able to give informed consent
  • Known decompensated liver cirrhosis (severe liver scarring that the liver can no longer cope with)
  • Not able to read and/or write in English

The registry criteria, word for word

Show all 3 criteriaShow less

Who can take part

  • Transgender individuals (18 years or older)
  • Individuals who are able to write and/or read in English. -

Who cannot take part

  • Inability to provide informed consent; Individuals with known decompensated liver cirrhosis

Where in United States

  • North Jersey AIDS Alliance dba North Jersey Community Research Initiative (NJCRI)Newark, United StatesEnrolling by invitation

About the trial

What the trial wants to find out

Primary Objective:

Read full original descriptionShow less

Assess disparities in liver health outcomes among transgender individuals on GAHT by evaluating liver function markers (transaminases, bilirubin levels, etc), as well as liver elasticity and presence of liver steatosis or Nonalcoholic Fatty Liver Disease (NAFLD) through FibroScan. A total of 60 participants will be recruited throughout the study, with a ratio of 1:1 between transgender participants who have been on GAHT more than 6 months ( = or > 182 days), and transgender participants who have been on GAHT for less than 6 months ( < 181 days) at the start of the study.

Secondary Objectives:

Assess liver health-related risk factors (e.g. obesity, alcohol consumption) in transgender population.

Investigate the association between specific hormone regimens and liver function in transgender individuals.

Explore potential modifiers of liver health outcomes, such as age, social barriers determinants of health, duration of hormone therapy and adherence to medical guidelines.

Change in Quality of Life from baseline to last study visit.

The group in the trial

  • Transgender >6 months on GAHT and Transgender <6 months on GAHT

    A total of 60 participants will be recruited throughout the study, with a ratio of 1:1 between transgender participants who have been on GAHT more than 6 months ( = or \> 182 days), and transgender participants who have been on GAHT for less than 6 months ( \< 181 days) at the start of the study

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
North Jersey Community Research Initiative (NJCRI) Study on Transgender Liver Health
Plain-language title
Liver health in transgender people taking gender-affirming hormone therapyGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
5 August 2026